ACB$3.55
Chart
Performance
Key Stats
AI ACB Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
NeutralAurora Cannabis shows mixed signals. While some fundamental aspects and long-term performance are positive, the company is facing profitability challenges and recent technical indicators suggest caution.
Thematic
The cannabis sector has significant growth potential, but Aurora Cannabis faces intense competition and evolving regulatory landscapes, creating moderate thematic tailwinds.
Fundamental
Aurora Cannabis shows significant revenue growth in recent periods but continues to struggle with profitability and positive free cash flow. The balance sheet appears manageable but requires careful monitoring.
Technical
The stock's short-term technicals are weak, with price below key moving averages and several oscillators indicating selling pressure. A bottoming process may be underway, but a clear trend reversal is not yet established.
| Factor | Score |
|---|---|
| Cannabis Market Growth | 70 |
| Regulatory Landscape | 40 |
| Competition | 45 |
| Innovation in Products | 60 |
| International Expansion | 55 |
| Factor | Score |
|---|---|
| Valuation | 70 |
| Profitability | 30 |
| Growth | 75 |
| Balance Sheet Health | 75 |
| Cash Flow | 40 |
| Factor | Score |
|---|---|
| Trend Analysis | 30 |
| Momentum | 40 |
| Volume Confirmation | 50 |
| Support & Resistance | 45 |
| Oscillators | 30 |
AI Investing Checklist
Powered by LiveAIBullish Points (7)
Strong Cash Position
The company has a substantial cash and cash equivalents balance of $137,921,000 as of 2025Q1, providing significant financial flexibility.
Positive Net Income in Latest Quarter
The company reported a net income of $1,591,000 in the most recent reported quarter (2025Q1), a significant improvement from the previous year's loss.
Bearish Points (8)
Negative Net Income Trend
The company has experienced significant net losses in prior periods (2024Q1, 2022Q2, 2021Q2), indicating a history of unprofitability.
Negative Price-to-Earnings Ratio
The trailing Price-to-Earnings (PE) ratio is negative (-51.9 TTM, -3.7 for 2024), signaling that the company is not currently profitable on a per-share basis.
Calendar
May 2020
11
Next Dividend Date
August 2025
5
Next Earnings Date
H: $
A: $
L: $
H: 99.60M
A: 96.83M
L: 93.80M
Profile
Aurora Cannabis Inc., together with its subsidiaries, engages in production, distribution, and sale of cannabis and cannabis-derivative products in Canada and internationally. It operates through two segments, Canadian Cannabis and Plant Propagation. The company offers medical and consumer cannabis products; sale of medical and consumer use cannabis products; and the propagation of vegetables and floral plants. Its medical cannabis brands include MedReleaf, CanniMed, Aurora and Whistler Medical Marijuana Co, as well as international brands, Pedanios, Bidiol, IndiMed and CraftPlant. The company was founded in 2013 and is headquartered in Edmonton, Canada.
Seasonals
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 98
Major Canadian cannabis producer and direct competitor with similar product lines, market share, and strategic focus to Aurora Cannabis.
Weight: 96
Significant Canadian cannabis producer and direct competitor with a broad portfolio including medical and adult-use products, and international operations.
Weight: 94
Canadian cannabis producer with strategic backing from Altria, a key player in the Canadian adult-use market and an emerging global presence.
Weight: 92
Canadian cannabis producer and retailer, diversifying into liquor retail, indicating broader consumer market ambitions and competition.